CLINICAL_TRIALS
trial_result
· 2013-06-14
Clinical Trial Update: Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders [Phase 2]
Summary
Open-label Phase 2 safety and tolerability study of STX209 in autism spectrum disorder with results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Seaside Therapeutics, Inc. | Conditions: Autism Spectrum Disorders | Phase 2 | Status: COMPLETED | Results posted: 2013-06-14